分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Sphingolipid metabolic enzyme GLA expression in gliomas: prognostic implications and therapeutic potential

Dan Wei, Qiuyang Su, Xiangkun Li, Hongbin Li, Dongyi Jin, Zhixiong Pan, Moujie Yang, Guihong Liu, Yuming Du, Wei Dong

Journal:Frontiers in Oncology

IF:3.3

DOI:10.3389/fonc.2026.1773193

PMID:41952691

Published:2026-03-24

research field:肿瘤学癌症代谢分子生物学生物信息学神经肿瘤学

Abstract

Background Gliomas are the most common primary brain tumors and show marked molecular heterogeneity and variable clinical outcomes, highlighting the need for reliable prognostic biomarkers. Methods We analyzed TCGA and CGGA datasets to identify prognosis-related genes in glioma and performed single-cell analysis and functional validation in glioma cell lines. Results Ten prognosis-related genes were identified, among which GLA showed the strongest association with survival. Elevated GLA expression was significantly associated with higher WHO grade, therapy resistance, and worse prognosis. Time-dependent ROC analysis showed favorable predictive performance for 1-, 3-, and 5-year survival. Single-cell RNA sequencing revealed preferential GLA expression in tumor-associated astrocytes and grade-dependent upregulation. GLA expression was associated with sphingolipid metabolism, hypoxia-related pathways, and ERAD-related pathways, including EDEM2 expression. In glioma cell lines, GLA knockdown suppressed cell viability and downregulated EDEM2. Cross-database analyses further supported the diagnostic and prognostic relevance of GLA across cohorts. Conclusion GLA may serve as a prognostic biomarker in glioma and is associated with metabolic and ERAD-related alterations, providing a potential direction for further mechanistic and therapeutic investigation.

本文使用的Yeasen产品

购物车
客服
转染试用